New drug IBI133 tested in 19 patients with Hard-to-Treat cancers
NCT ID NCT06170190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called IBI133 in 19 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals were to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body and whether it shows any signs of shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Hard-to-Treat cancers by homing in on a specific protein
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug NEOK001 targets Hard-to-Treat cancers in first human trial
- New drug aims to shrink hard-to-treat tumors
- New drug IBI343 takes on advanced cancers in first human trial